Epigenomics and BioChain enter into collaboration in China

29-Oct-2013 - Epigenomics AG and BioChain announced that the companies have signed an agreement regarding a broad strategic collaboration of both companies. In addition, BioChain will acquire 217,935 newly issued shares of the company which corresponds to an investment of US$ 1.3m (EUR 0.94m) into ...

Epigenomics signs agreement with Polymedco

04-Oct-2013 - Epigenomics AG announced that it has entered into a joint commercialization agreement with Polymedco Inc., a leading provider of colorectal cancer tests in North America. Both companies will jointly commercialize Epi proColon®, Epigenomics' blood-based test for colorectal cancer (CRC) screening, ...

Epigenomics Biomarker Predicts Drug Resistance in Colorectal Cancer

09-Jan-2012 - Epigenomics AG announced the publication of a study authored by Professor Matthias Ebert at University of Heidelberg entitled “TFAP2E-DKK4 and Chemoresistance in Colorectal Cancer” in The New England Journal of Medicine.In this study involving more than 200 patients in four independent cohorts, ...

Epigenomics AG: Noel Doheny Appointed as New CEO of US-Subsidiary Epigenomics Inc.

26-Apr-2011 - Epigenomics AG announced the appointment of Noel Doheny as the new Chief Executive Officer (CEO) of its subsidiary Epigenomics Inc. in Seattle, WA, USA, reporting to Geert Nygaard, CEO of Epigenomics AG. Mr. Doheny will start in his new position in early May 2011. Mr. Doheny has 30+ years of ...

Epigenomics AG and NextPharma Sign Global Manufacturing Deal for Colorectal Cancer Blood Test

08-Oct-2010 - Epigenomics AG and NextPharma Technologies announced that the companies have signed a global manufacturing contract for Epigenomics' Epi proColon product. Epi proColon, currently marketed in Europe, is the world's first in-vitro diagnostic test for the detection of colorectal cancer in a simple ...

Epigenomics: Licensee ARUP Laboratories Launches Septin9 Colorectal Cancer Blood Test in the United States

22-Jul-2010 - Epigenomics AG reports that its licensee ARUP Laboratories, Salt Lake City, UT, U.S.A., today has announced the launched of a laboratory-developed test for the blood-based detection of colorectal cancer. The test is based on Epigenomics' proprietary Septin9 biomarker and DNA ...

Epigenomics AG Successfully Validates Lung Cancer Test in Clinical Trial

24-Jun-2010 - Epigenomics AG successfully completed the pivotal performance evaluation study for its Epi proLung BL Reflex Assay, a lung cancer diagnostic test. The test determines the DNA methylation status of the SHOX2 gene in bronchial lavage material routinely obtained during the clinical workup of ...

Epigenomics AG Licenses Biomarker for Colorectal Cancer Blood Test Screening to Canadian Warnex Medical Laboratories

04-May-2010 - Epigenomics AG and Warnex Medical Laboratories, a division of Warnex Inc., announced that they have signed a non-exclusive licensing agreement for Epigenomics' colorectal cancer biomarker Septin9. Under the terms of the agreement, Warnex has obtained the rights to establish a laboratory-developed ...

Epigenomics AG Receives Allowance for Key Technology Patent in Japan

Patent broadly covers HeavyMethyl, a core technology of Epigenomics' molecular diagnostic products

15-Mar-2010 - Epigenomics AG announced that it received a Notice of Allowance by the Japanese Patent Office stating that they intend to grant a patent for Epigenomics' HeavyMethyl(TM) technology. This notification is equivalent to a "Rule 71(3) notification" by the European Patent Office. Patent application ...

U.S. Development Partner Quest Diagnostics Completes Clinical Development of Septin9 Colorectal Cancer Blood Test

04-Nov-2009 - Epigenomics AG announced that Quest Diagnostics Incorporated successfully completed the clinical validation of its Septin9-based laboratory-developed test for aiding the detection of colorectal cancer. Under terms of a license agreement between the companies for Epigenomics' proprietary DNA ...